Product Theater for Zepbound® (tirzepatide) Injection

Overview

Join a presentation from one of your peers on the efficacy, safety, dosing, and administration of once-weekly Zepbound®. Learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to ask questions at the conclusion of the program. Refreshments will be provided.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Please see Full Prescribing Information including Boxed Warning and Medication Guide at the product theater or on https://zepbound.lilly.com.

Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Program Objectives

Upon completion of the program, participants will have learned the following about Zepbound:

· Mechanism of action
· Clinical trial data, including efficacy and safety findings
· Dosing and administration information
· How to get appropriate patients started